5-10 business days

Taselisib has a dual mechanism of action, both blocking kinase signaling and inducing down-regulation of the mutant p110alpha protein level in a dose-dependent and time-dependent manner. The taselisib-induced degradation of mutant p110a protein is ubiquitin-mediated and proteasome-dependent.

Product Name Taselisib
CAS Number 1282512-48-4
Related CAS
Molecular Formula C24H28N8O2
Molecular Weight 460.542
Purity (HPLC) >= 95%
Physical Appearance White solid
Solubility DMSO, DMF
Shipping Conditions Room Temperature
Storage Conditions Refrigerated
Shelf Life 12 months after the date of delivery
Regulatory Statement For Research Use Only


Li, H., Dong, J., Cai, M., Xu, Z., Cheng, X.-D.,Qin, J.-J., Protein degradation technology: a strategic paradigm shift in drug discovery. Journal of Hematology & Oncology 2021, 14, 138.Friedman, L., Edgar, K., Song, K., Schmidt, S., Kirkpatrick, D., Phu, L., Nannini, M., Hong, R., Cheng, E., Crocker, L., Young, A.,Sampath, D., Abstract S6-04: The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action. Cancer Research 2017, 77, S6-04-S6-04.



Datasheet         COA           MSDS



If you know of a paper that uses this product from Tenova Pharma, please let us know.